Previous 10 | Next 10 |
BTIG analyst Kaveri Pohlman assumed coverage of Replimune Group (NASDAQ:REPL) with a Buy rating and $60 price target (PT), implying a premium of ~93% from last close. The analyst assumed coverage of 10 more Immuno-oncology companies, and believes "much of the most promising work" involves bro...
Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroesophageal cancer AbCell...
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming September 2021 virtual investor conferences. Citi’s 16th Annual Virtua...
All five clinical-stage molecules continue to advance with six ongoing randomized Phase 2 and Phase 3 studies in major tumor types, including lung, colon, prostate and pancreatic cancer AB521, a small molecule HIF-2α inhibitor, expected to enter the clinic in 4Q21 ...
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 1:45 p.m. Eastern ...
Company to Host Conference Call on Thursday, August 5, 2021, at 1:30 pm PT/4:30 pm ET Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the company will report its fin...
JuSun/iStock via Getty Images During the week ended June 25, 2021, Healthcare sector rose 2.01% and Healthcare Select Sector SPDR ETF (XLV) gained 1.58% compared to weekly gain of 2.82% of S&P 500 ETF. Leading the top gainers pack was Atossa Therapeutics (ATO...
After the market closed on Wednesday, Arcus Biosciences (NYSE: RCUS) presented interim results from Arc-7 -- one of the most closely watched phase 2 clinical trials of the year. According to the company, patients who received the company's anti-Tigit antibody, domvanalimab, showed e...
Shares of Arcus Biosciences (NYSE: RCUS) , a clinical-stage biopharmaceutical company, are on the move following a progress report for the company's most valuable asset at the moment. Investors hoping Gilead Sciences (NASDAQ: GILD) will exercise an option to license domvanal...
Gainers: Kaleido Biosciences (KLDO) +15%, Pieris Pharmaceuticals (PIRS) +14%, Arcus Biosciences (RCUS) +14%, Compugen (CGEN) +14%, Atossa Therapeutics (ATOS) +14%.Losers: Portage Biotech (PRTG) -23%, Rite Aid (RAD) -14%, 4D Mole...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...